Bioactive Flavaglines: Synthesis and Pharmacology

Archive ouverte

Basmadjian, Christine | Zhao, Qian | Gramont, Armand De | Serova, Maria | Faivre, Sandrine | Raymond, Eric | Vagner, Stephan | Robert, Caroline | Nebigil, Canan G. | Désaubry, Laurent

Edité par CCSD ; Wiley -

International audience. Flavaglines represent a family of more than 100 cyclopenta[b]benzofurans that are found in medicinal plants of the genus Aglaia in South-East Asia. These compounds display potent anti-inflammatory, neuroprotective, cardioprotective, and above all, anticancer activities. The most amazing feature of flavaglines is their ability to kill cancer cells without affecting normal cells. Additionally, flavaglines protect neurons and cardiac cells from many types of stresses. Such a selective cytotoxicity to cancer cells and cytoprotection of normal cells, both of which occur at nanomolar concentrations, is unprecedented. This unique pharmacological profile of activity is now being rationalized with the recent discovery of their molecular targets, the scaffold proteins prohibitins and the translation initiation factor eIF4A (eukaryotic initiation factor-4A). This chapter aims to describe the synthetic routes to flavaglines, their mechanism of action, the evaluation of their biological potency, and ongoing effort to provide novel therapeutic agents.

Consulter en ligne

Suggestions

Du même auteur

Cancer wars: natural products strike back

Archive ouverte | Basmadjian, Christine | CCSD

International audience

FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity

Archive ouverte | Qureshi, Rehana | CCSD

International audience. Aims: The clinical use of doxorubicin for the treatment of cancer is limited by its cardiotoxicity. Flavaglines are natural products that have both potent anticancer and cardioprotective prop...

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines

Archive ouverte | Malka-Mahieu, Hélène | CCSD

Activating mutations of the NRAS (neuroblastoma rat sarcoma viral oncogene) protein kinase, present in many cancers, induce a constitutive activation of both the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signal trans...

Chargement des enrichissements...